Sussman Joel F. 4

4 · Galera Therapeutics, Inc. · Filed Nov 16, 2020

Form 4

Period: 2020-11-12

Chief Accounting Officer

Transactions

Exercise/Conversion
Common Stock
2020-11-12$1.07/sh+10,000$10,700→ 10,000 total
Sale
Common Stock
2020-11-12$10.06/sh−10,000$100,627→ 0 total
Exercise/Conversion
Common Stock
2020-11-13$1.14/sh+3,755$4,281→ 7,361 total
Exercise/Conversion
Stock Option (Right to Buy)
2020-11-12−10,000→ 3,606 total
Exercise: $1.07Exp: 2023-01-22→ Common Stock (10,000 underlying)
Exercise/Conversion
Stock Option (Right to Buy)
2020-11-13−3,606→ 0 total
Exercise: $1.07Exp: 2023-01-22→ Common Stock (3,606 underlying)
Exercise/Conversion
Stock Option (Right to Buy)
2020-11-13−2,639→ 32,238 total
Exercise: $2.43Exp: 2026-03-01→ Common Stock (2,639 underlying)
Exercise/Conversion
Common Stock
2020-11-13$1.07/sh+3,606$3,858→ 3,606 total
Exercise/Conversion
Common Stock
2020-11-13$2.43/sh+2,639$6,413→ 10,000 total
Sale
Common Stock
2020-11-13$10.32/sh−10,000$103,197→ 0 total
Exercise/Conversion
Stock Option (Right to Buy)
2020-11-13−3,755→ 0 total
Exercise: $1.14Exp: 2024-09-16→ Common Stock (3,755 underlying)

Footnotes (3)

[F1]The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $10.00 to $10.25. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
[F2]The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $10.00 to $10.75. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
[F3]The option has fully vested and is currently exercisable.

Documents

1 file